Subscribe to Newsletter to get latest insights & analysis in your inbox. Download the ETPharma App and get the Realtime updates and Save your favourite articles. The cases are among a wave of patent lawsuits from biotech companies seeking royalties for the technology used in the blockbuster vaccines.A Moderna spokesperson said that the company would defend itself against BioNTech's case. BioNTech did not immediately respond to a request for comment on the new lawsuit.Spokespeople for Pfizer, which is not directly involved in the lawsuit, also did not immediately comment.mNEXSPIKE is expected to account for 55% of Moderna's COVID vaccine revenue through the 2025-26 respiratory virus season, BioNTech's lawsuit said. (Reporting by Blake Brittain in Washington; editing by Barbara Lewis and Deepa Babington)>
